SG11201809783RA - Dna monoclonal antibodies targeting influenza virus - Google Patents
Dna monoclonal antibodies targeting influenza virusInfo
- Publication number
- SG11201809783RA SG11201809783RA SG11201809783RA SG11201809783RA SG11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA
- Authority
- SG
- Singapore
- Prior art keywords
- influenza
- international
- published
- monoclonal antibodies
- influenza virus
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title abstract 2
- 241000712461 unidentified influenza virus Species 0.000 title abstract 2
- 206010022000 influenza Diseases 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 241000702620 H-1 parvovirus Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000037797 influenza A Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/192946 Al 09 November 2017 (09.11.2017) W I P0 I P C T (51) International Patent Classification: (74) Agent: NGUYEN, Quang, D. et al.; Riverside Law, LLP, C07K 16/08 (2006.01) A61K 48/00 (2006.01) Glenhardie Corporation Center, 1285 Drummers Lane, C07K 16/00 (2006.01) Suite 202, Wayne, PA 19087 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/031213 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 05 May 2017 (05.05.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/332,381 05 May 2016 (05.05.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 62/376,162 17 August 2016 (17.08.2016) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: WEINER, David [US/US]; 717 Beacon Lane, (84) Designated States (unless otherwise indicated, for every Merion, PA 19066 (US). kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants: ELLOTT, Sarah [US/US]; P.O.Box 301, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — Pullman, WA 99163 (US). PATEL, Ami [US/US]; 1 EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Rainey Court, Philadelphia, PA 19103 (US). YAN, Man — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = [US/US]; 503 Sheffild Drive, Wallingford, PA 19086 (US). = (54) Title: DNA MONOCLONAL ANTIBODIES TARGETING INFLUENZA VIRUS DMAb 5J8 construct = = = Influenza DMAb contain variable regions i- . 5J8 from anti-influenza monoclonal = published =fi a antibodies = = = 5 J8 (Krause et al, J Virol, 2011) = • Binds to receptor binding pocket on = variable globular head • Cross-reactive to multiple influenza-A H1 viruses 1-1 7r tz. Influenza Hemacialutinin ei tz Figure 1 • —I Ir -- - 1 -1 (57) : Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemag- N glutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said com- _ position and method of generation. [Continued on next page] WO 2017/192946 Al MIDEDIMOMMIDIRMEMOMOICHOMMODEVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332381P | 2016-05-05 | 2016-05-05 | |
US201662376162P | 2016-08-17 | 2016-08-17 | |
PCT/US2017/031213 WO2017192946A1 (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting influenza virus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809783RA true SG11201809783RA (en) | 2018-12-28 |
Family
ID=60203613
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809783RA SG11201809783RA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting influenza virus |
SG10202011021XA SG10202011021XA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting influenza virus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011021XA SG10202011021XA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting influenza virus |
Country Status (11)
Country | Link |
---|---|
US (2) | US11851477B2 (en) |
EP (1) | EP3452504A4 (en) |
JP (2) | JP7506869B2 (en) |
KR (3) | KR20230125851A (en) |
CN (2) | CN118109478A (en) |
AU (2) | AU2017261305B2 (en) |
BR (1) | BR112018072708A2 (en) |
CA (1) | CA3023093A1 (en) |
MX (1) | MX2018013521A (en) |
SG (2) | SG11201809783RA (en) |
WO (1) | WO2017192946A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190284261A1 (en) * | 2016-11-07 | 2019-09-19 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs for use against lyme disease |
WO2023081471A1 (en) * | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040087521A1 (en) * | 1993-03-18 | 2004-05-06 | Merck & Co., Inc. | Nucleic acid pharmaceuticals-influenza matrix |
CN101541832B (en) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
US8975378B2 (en) * | 2008-12-25 | 2015-03-10 | Osaka University | Human anti-human influenza virus antibody |
WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
SI2734545T1 (en) * | 2011-07-18 | 2019-06-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
EP2814841A4 (en) * | 2012-01-31 | 2015-06-17 | Univ Osaka | Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same |
CN104853782A (en) | 2012-12-13 | 2015-08-19 | 宾夕法尼亚大学理事会 | DNA antibody constructs and method of using same |
WO2015089492A2 (en) | 2013-12-13 | 2015-06-18 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
US11278619B2 (en) * | 2014-12-01 | 2022-03-22 | The Trustees Of The University Of Pennsylvania | DNA antibody constructs and method of using same |
CA3018566A1 (en) * | 2016-03-21 | 2017-09-28 | David B. Weiner | Dna antibody constructs and method of using same |
-
2017
- 2017-05-05 SG SG11201809783RA patent/SG11201809783RA/en unknown
- 2017-05-05 JP JP2019510570A patent/JP7506869B2/en active Active
- 2017-05-05 KR KR1020237027640A patent/KR20230125851A/en active Application Filing
- 2017-05-05 BR BR112018072708-3A patent/BR112018072708A2/en unknown
- 2017-05-05 WO PCT/US2017/031213 patent/WO2017192946A1/en unknown
- 2017-05-05 AU AU2017261305A patent/AU2017261305B2/en active Active
- 2017-05-05 CN CN202410237536.9A patent/CN118109478A/en active Pending
- 2017-05-05 CN CN201780042120.XA patent/CN110325546B/en active Active
- 2017-05-05 US US16/098,921 patent/US11851477B2/en active Active
- 2017-05-05 SG SG10202011021XA patent/SG10202011021XA/en unknown
- 2017-05-05 CA CA3023093A patent/CA3023093A1/en active Pending
- 2017-05-05 MX MX2018013521A patent/MX2018013521A/en unknown
- 2017-05-05 EP EP17793413.0A patent/EP3452504A4/en active Pending
- 2017-05-05 KR KR1020187035167A patent/KR102375324B1/en active IP Right Grant
- 2017-05-05 KR KR1020227008096A patent/KR20220035288A/en not_active IP Right Cessation
-
2022
- 2022-05-11 JP JP2022078109A patent/JP2022116034A/en active Pending
-
2023
- 2023-11-16 US US18/511,108 patent/US20240150442A1/en active Pending
-
2024
- 2024-05-17 AU AU2024203297A patent/AU2024203297A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220035288A (en) | 2022-03-21 |
CN118109478A (en) | 2024-05-31 |
JP2022116034A (en) | 2022-08-09 |
CN110325546B (en) | 2024-03-19 |
BR112018072708A2 (en) | 2019-02-19 |
AU2024203297A1 (en) | 2024-06-13 |
WO2017192946A8 (en) | 2018-12-27 |
EP3452504A4 (en) | 2020-07-29 |
JP7506869B2 (en) | 2024-06-27 |
AU2017261305B2 (en) | 2024-06-13 |
US20240150442A1 (en) | 2024-05-09 |
US20190135899A1 (en) | 2019-05-09 |
CA3023093A1 (en) | 2017-11-09 |
CN110325546A (en) | 2019-10-11 |
EP3452504A1 (en) | 2019-03-13 |
AU2017261305A1 (en) | 2018-12-20 |
KR20230125851A (en) | 2023-08-29 |
JP2019521702A (en) | 2019-08-08 |
WO2017192946A1 (en) | 2017-11-09 |
MX2018013521A (en) | 2019-06-10 |
SG10202011021XA (en) | 2020-12-30 |
AU2017261305A8 (en) | 2019-08-08 |
US11851477B2 (en) | 2023-12-26 |
KR20190035614A (en) | 2019-04-03 |
KR102375324B1 (en) | 2022-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201809789SA (en) | Dna monoclonal antibodies targeting checkpoint molecules | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201808152PA (en) | Dna antibody constructs and method of using same | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
SG11201809778TA (en) | Dna antibody constructs for use against pseudomonas aeruginosa | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods |